NASDAQ:LGND - Nasdaq - US53220K5048 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to LGND. LGND was compared to 198 industry peers in the Pharmaceuticals industry. LGND is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. LGND has a correct valuation and a medium growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -0.43% | ||
ROE | -0.49% | ||
ROIC | 2.01% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 13.77% | ||
PM (TTM) | N/A | ||
GM | 93.37% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 12.59 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 8.93 | ||
Quick Ratio | 8.55 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 18.93 | ||
Fwd PE | 17.31 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 21.86 | ||
EV/EBITDA | 25.02 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
108.07
-0.48 (-0.44%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 18.93 | ||
Fwd PE | 17.31 | ||
P/S | 12.45 | ||
P/FCF | 21.86 | ||
P/OCF | 21.45 | ||
P/B | 2.51 | ||
P/tB | 7.61 | ||
EV/EBITDA | 25.02 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -0.43% | ||
ROE | -0.49% | ||
ROCE | 2.54% | ||
ROIC | 2.01% | ||
ROICexc | 3.91% | ||
ROICexgc | N/A | ||
OM | 13.77% | ||
PM (TTM) | N/A | ||
GM | 93.37% | ||
FCFM | 56.98% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 5.17% | ||
Cap/Sales | 1.09% | ||
Interest Coverage | 87.53 | ||
Cash Conversion | 166.58% | ||
Profit Quality | N/A | ||
Current Ratio | 8.93 | ||
Quick Ratio | 8.55 | ||
Altman-Z | 12.59 |